Biovica International AB (BIOVIC-B) Fair Value & Analysis
Healthcare · SE · Market cap 117M SEK (≈ $12.2M) · ISIN SE0008613731
What is Biovica International AB really worth?
Below-average quality, and trading another 136% above our fair value of kr 0.1785.
Risks
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 22 days ago
Share price −17.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 0.2295). The favourable scenario is already priced in.
- Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.1190 to kr 0.2295) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 0.2750 – kr 65.40 · fair‑value band kr 0.1190 – kr 0.2295 · the kr 0.4210 price screens above the kr 0.1785 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Biovica International AB (BIOVIC-B) currently trades at kr 0.4210, while our model-based Fair Value estimate is kr 0.1785, implying the stock looks roughly 135.8% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at 10.9M SEK. Revenue grew 45.7% year over year. It earns a return on equity of −83.9%. The balance sheet holds a net cash position of 66.1M SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 0.1190 (bear case) to kr 0.2295 (bull case); at kr 0.4210, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 53% below its 52-week high and 56% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at −58%, BIOVIC-B screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when BIOVIC-B reaches fair value
Put BIOVIC-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 37 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer.
Full company description
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Biovica International AB reported revenue of 13.4M SEK in FY2026 versus 2.0M SEK in FY2022, a compound +59.9%/yr. Reported net income was −69.9M SEK in FY2026.
BIOVIC-B screens 136% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Biovica International AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Biovica International AB (BIOVIC-B) overvalued or undervalued?
What is the fair value of BIOVIC-B?
What is the quality score of BIOVIC-B?
What is the revenue of Biovica International AB (BIOVIC-B)?
What is the net profit margin of BIOVIC-B?
Watch Biovica International AB in the live analysis
One click puts Biovica International AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.